Patents by Inventor Robert Dally

Robert Dally has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RAF KINASE INHIBITORS
    Publication number: 20120178780
    Abstract: Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se.
    Type: Application
    Filed: March 19, 2012
    Publication date: July 12, 2012
    Inventors: Jill E. WOOD, Hanno Wild, Daniel H. Rogers, John Lyons, Michael Katz, Yolanda Caringal, Robert Dally, Wendy Lee, Roger A. Smith, Cheri Blum
  • Raf Kinase Inhibitors
    Publication number: 20100063088
    Abstract: Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se.
    Type: Application
    Filed: November 17, 2009
    Publication date: March 11, 2010
    Inventors: Jill E. WOOD, Hanno Wild, Daniel H. Rogers, John Lyons, Michael Katz, Yolanda Caringal, Robert Dally, Wendy Lee, Roger A. Smith, Cheri Blum
  • 3-(2-Acylamino-1-Hydroxyethyl)-Morpholine Derivatives and Their Use as Bace Inhibitors
    Publication number: 20070225267
    Abstract: The present invention provides BACE inhibitors of Formula (I); methods for their use and preparation, and intermediates useful for their preparation.
    Type: Application
    Filed: September 20, 2005
    Publication date: September 27, 2007
    Inventors: Howard Broughton, Robert Dally, Timothy Durham, Maria Rosario Gonzalez-Garcia, Lilly Sa, Patric Hahn, Kenneth Henry, Todd Kohn, James McCarthy, Timothy Shepherd, Jon Erickson, Ana Bueno Melendo
  • PYRROLIDINE DERIVATIVES USEFUL AS BASE INHIBITORS
    Publication number: 20070213331
    Abstract: The present invention provides BACE inhibitors of Formula I: methods for their use and preparation, and intermediates for their preparation.
    Type: Application
    Filed: April 8, 2005
    Publication date: September 13, 2007
    Inventors: Robert Dally, Timothy Shepherd, David Bender, Maria Rojo Garcia
  • Selective estrogen receptor modulators
    Publication number: 20070111988
    Abstract: The present invention relates to a selective estrogen receptor modulators of formula I (I); or a pharmaceutical acid addition salt thereof; and of formula II (II); or a pharmaceutical salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.
    Type: Application
    Filed: January 18, 2005
    Publication date: May 17, 2007
    Applicant: ELI LILLY AND COMPANY
    Inventors: Robert Dally, Jeffrey Dodge, Conrad Hummel, Scott Jones, Timothy Shepherd, Owen Wallace, Wayne Weber
  • Selective estrogen receptor modulators containing a phenylsulfonyl group
    Publication number: 20060183736
    Abstract: The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.
    Type: Application
    Filed: July 16, 2003
    Publication date: August 17, 2006
    Inventors: Robert Dally, Jeffrey Dodge, Scott Frank, Scott Jones, Timothy Shepherd, Owen Wallace, Kin Fong, Conrad Hummel, George Lewis
  • Benzimidazoles and benzothiazoles as inhibitors of map kinase
    Publication number: 20050272791
    Abstract: The present invention provides kinase inhibitors of Formula I: wherein W represents inter alia imidazol, oxazol, pyrazol, thiazol as triazol, which are substituted by phenyl or thienyl. The disclosed compounds inhibit p-38 kinase and are useful in the treatment of metastasis or rheumatoid arthritis.
    Type: Application
    Filed: July 31, 2003
    Publication date: December 8, 2005
    Applicant: Eil Lilly and Company
    Inventors: Rosanne Bonjouklian, Jose De Diego Gomez, Alfonso De Dios, Chafiq Hamdouchi, Tiecho Li, Beatriz De Uralde Garmendia, Michal Vieth, Jeremy York, Robert Dally, Miriam Del Prado Catalina, Carlos Jaramillo Aguado, Luisa Martin-Cabrejas, Carlos Montero Salgado, Sheila Pleite Selgas, Concepcion Sanchez-Martinez, Timothy Shepherd, James Wikel
  • Raf kinase inhibitors
    Publication number: 20050256174
    Abstract: Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se.
    Type: Application
    Filed: June 10, 2005
    Publication date: November 17, 2005
    Inventors: Jill Wood, Hanno Wild, Daniel Rogers, John Lyons, Michael Katz, Yolanda Caringal, Robert Dally, Wendy Lee, Roger Smith, Cheri Blum
  • 2,6-Substituted chroman derivatives useful as beta-3 adrenoreceptor agonists
    Publication number: 20050215594
    Abstract: This invention relates to novel 2,6-substituted chroman derivatives which are useful in the treatment of beta-3 adrenoreceptor-mediated conditions.
    Type: Application
    Filed: April 28, 2005
    Publication date: September 29, 2005
    Applicant: Bayer Pharmaceuticals Corporation
    Inventors: Stephen O'Connor, Gaetan Ladouceur, William Bullock, Ann-Marie Campbell, Miao Dai, Robert Dally, Jacques Dumas, Holia Hatoum-Mokdad, Uday Khire, Wendy Lee, Qingjie Liu, Derek Lowe, Steven Magnuson, Ning Qi, Tatiana Skelekhin, Quanrong Shen, Roger Smith, Ming Wang
  • 2,6-substituted chroman derivatives useful as beta-3 adrenoreceptor agonists
    Patent number: 6919371
    Abstract: This invention relates to novel 2,6-substituted chroman derivatives which are useful in the treatment of beta-3 adrenoreceptor-mediated conditions.
    Type: Grant
    Filed: September 17, 2003
    Date of Patent: July 19, 2005
    Assignee: Bayer Pharmaceuticals Corporation
    Inventors: Stephen J. O'Connor, Gaetan H. Ladouceur, William H. Bullock, Ann-Marie Campbell, Miao Dai, Robert Dally, Jacques Dumas, Holia N. Hatoum-Mokdad, Uday Khire, Wendy Lee, Qingjie Liu, Derek B. Lowe, Steven R. Magnuson, Ning Qi, Tatiana E. Shelekhin, Quanrong Shen, Roger A. Smith, Ming Wang
  • 2,6-Substituted chroman derivatives useful as beta-3 adrenoreceptor agonists
    Publication number: 20040072828
    Abstract: This invention relates to novel 2,6-substituted chroman derivatives which are useful in the treatment of beta-3 adrenoreceptor-mediated conditions.
    Type: Application
    Filed: September 17, 2003
    Publication date: April 15, 2004
    Applicant: Bayer Pharmaceuticals Corporation
    Inventors: Stephen J. O'Connor, Gaetan H. Ladouceur, William H. Bullock, Ann-Marie Campbell, Miao Dai, Robert Dally, Jacques Dumas, Holia N. Hatoum-Mokdad, Uday Khire, Wendy Lee, Qingjie Liu, Derek B. Lowe, Steven R. Magnuson, Ning Qi, Tatiana E. Shelekhin, Quanrong Shen, Roger A. Smith, Ming Wang
  • Cyclic and acyclic amidines and pharmaceutical compositions containing them for use as progesterone receptor binning agents
    Publication number: 20030229072
    Abstract: Disclosed are cyclic and acyclic amidines, pharmaceutical compositions containing such amidines, and their use in treating or preventing progesterone receptor mediated diseases or conditions, such as osteopenia and osteoporosis.
    Type: Application
    Filed: March 3, 2003
    Publication date: December 11, 2003
    Inventors: William H Bullock, Harold C E Kluender, William L Collibee, Robert Dally, Martha E Rodriguez, Ming Wang
  • 2,6-Substituted chroman derivatives useful as beta-3 adrenoreceptor agonists
    Patent number: 6660752
    Abstract: This invention relates to novel 2,6-substituted chroman derivatives which are useful in the treatment of beta-3 adrenoreceptor-mediated conditions.
    Type: Grant
    Filed: April 22, 2002
    Date of Patent: December 9, 2003
    Assignee: Bayer Pharmaceuticals Corporation
    Inventors: Stephen J. O'Connor, Gaetan H. Ladouceur, William H. Bullock, Ann-Marie Campbell, Miao Dai, Robert Dally, Jacques Dumas, Holia N. Hatoum-Mokdad, Uday Khire, Wendy Lee, Qingjie Liu, Derek B. Lowe, Steven R. Magnuson, Ning Qi, Tatiana E. Shelekhin, Quanrong Shen, Roger A. Smith, Ming Wang
  • Substituted 2-arylimino heterocycles and compositions containing them for use as progesterone receptor binding agents
    Publication number: 20030207865
    Abstract: This invention relates to 2-arylimino heterocycles, including 2-arylimino-1,3-thiazolidines, 2-arylimino-2,3,4,5-tetrahydro-1,3-thiazines, 2-arylimino-1,3-thiazolidin-4-ones, 2-arylimino-1,3-thiazolidin-5-ones, and 2-arylimino-1,3-oxazolidines, and their use in modulating progesterone receptor mediated processes, and pharmaceutical compositions for use in such therapies.
    Type: Application
    Filed: October 23, 2001
    Publication date: November 6, 2003
    Inventors: Brian R. Dixon, Cedo M. Bagi, Catherine R. Brennan, David R. Brittelli, William H. Bullock, Jinshan Chen, William L. Collibee, Robert Dally, Jeffrey S. Johnson, Harold C. E. Kluender, William F. Lathrop, Peiying Liu, Carol Ann Mase, Aniko M. Redman, William J. Scott, Klaus Urbahns, Donald J. Wolanin
  • 2,6-Substituted chroman derivatives useful as beta-3 adrenoreceptor agonists
    Publication number: 20030078260
    Abstract: This invention relates to novel 2,6-substituted chroman derivatives which are useful in the treatment of beta-3 adrenoreceptor-mediated conditions.
    Type: Application
    Filed: April 22, 2002
    Publication date: April 24, 2003
    Inventors: Stephen J. O'Connor, Gaetan H. Ladouceur, William H. Bullock, Ann-Marie Campbell, Miao Dai, Robert Dally, Jacques Dumas, Holia N. Hatoum-Mokdad, Uday Khire, Wendy Lee, Qingjie Liu, Derek B. Lowe, Steven R. Magnuson, Ning Qi, Tatiana E. Shelekhin, Quanrong Shen, Roger A. Smith, Ming Wang
  • Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents
    Patent number: 6353006
    Abstract: This invention relates to 2-arylimino heterocycles, including 2-arylimino-1,3-thiazolidines, 2-arylimino-2,3,4,5-tetrahydro-1,3-thiazines, 2-arylimino-1,3-thiazolidin-4-ones, 2-arylimino-1,3-thiazolidin-5-ones, and 2-arylimino-1,3-oxazolidines, and their use in modulating progesterone receptor mediated processes, and pharmaceutical compositions for use in such therapies.
    Type: Grant
    Filed: December 3, 1999
    Date of Patent: March 5, 2002
    Assignee: Bayer Corporation
    Inventors: Brian R. Dixon, Cedo M. Bagi, Catherine R. Brennan, David R. Brittelli, William H. Bullock, Jinshan Chen, William L. Collibee, Robert Dally, Jeffrey S. Johnson, Harold C. E. Kluender, William F. Lathrop, Peiying Liu, Carol Ann Mase, Anikó M. Redman, William J. Scott, Klaus Urbahns, Donald J. Wolanin
  • Raf kinase inhibitors
    Publication number: 20010006975
    Abstract: Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se.
    Type: Application
    Filed: January 8, 2001
    Publication date: July 5, 2001
    Applicant: BAYER CORPORATION and ONYX PHARMACEUTICALS West Haven, CT and Richmond, CA, respectively
    Inventors: Jill E. Wood, Hanno Wild, Daniel H. Rogers, John Lyons, Michael Katz, Yolanda Caringal, Robert Dally, Wendy Lee, Roger A. Smith, Cheri Blum
  • Inhibition of raf kinase activity using aryl ureas
    Patent number: 6187799
    Abstract: Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se.
    Type: Grant
    Filed: May 22, 1998
    Date of Patent: February 13, 2001
    Assignees: Onyx Pharmaceuticals, Bayer Corporation
    Inventors: Jill E Wood, Hanno Wild, Daniel H Rogers, John Lyons, Michael Katz, Yolanda Caringal, Robert Dally, Wendy Lee, Roger A. Smith, Cheri Blum
  • Method for stabilizing vinyl chloride polymers
    Patent number: 4085077
    Abstract: The presence of free carboxylic acids containing from 8 to 20 carbon atoms or the anhydrides of these acids inhibits the rate of heat induced discoloration exhibited by certain polymer formulations containing as a heat stabilizer the reaction product of a carboxylic acid with a stoichiometric excess, based on the number of carboxyl groups present, of a diorganotin oxide. The free acids are virtually ineffective heat stabilizers for these polymers in the absence of the aforementioned reaction product. The polymers which can be stabilized include vinyl chloride polymers and acrylonitrile-butadiene-styrene terpolymers.
    Type: Grant
    Filed: February 23, 1976
    Date of Patent: April 18, 1978
    Assignee: M&T Chemicals Inc.
    Inventors: Robert Dally Dworkin, Adam Joseph Ejk
  • One step method for preparing non-stoichiometric diorganotin carboxylates using a solid phase reaction
    Patent number: 4032552
    Abstract: Diorganotin carboxylates containing more than 1 mole of tin for every 2 moles of carboxylic acid ##STR1## residues are prepared by a solid state reaction between a diorganotin oxide and a dicarboxylic acid anhydride. Depending upon the temperature of the oxide-anhydride mixture, the reaction is substantially complete in from less than 1 to up to 48 hours and produces no by-products.
    Type: Grant
    Filed: June 12, 1975
    Date of Patent: June 28, 1977
    Assignee: M & T Chemicals Inc.
    Inventors: Robert Dally Dworkin, Adam Joseph Ejk